← All indications
Nephrosis
Pathological processes of the KIDNEY without inflammatory or neoplastic components. Nephrosis may be a primary disorder or secondary complication of other diseases. It is characterized by the NEPHROTIC SYNDROME indicating the presence of PROTEINURIA and HYPOALBUMINEMIA with accompanying EDEMA.
Subtype terms (2)
More specific conditions that are subtypes of Nephrosis in the MeSH hierarchy.
- Nephrosis, Lipoid
15 drugs (10 approved, 5 experimental)
- Nephrotic Syndrome
55 drugs (46 approved, 9 experimental)
Drugs by status
Organizations
Organization Involved with Phase 4 Indications (32)
- Astellas
- Mallinckrodt
- Chong Kun Dang Pharmaceutical
- National Institutes of Health (NIH)
- Huazhong University of Science and Technology
- Aarhus University
- Central South University
- Arizona Kidney Disease and Hypertension Center
- University of London
- Nanjing Medical University
- Nilratan Sircar Medical College
- Northwell Health
- Rhode Island Hospital
- Seoul National University
- University of Leicester
- University of Tehran
- University of Athens
- Columbia University
- Fudan University
- Peking University
- Southeast Renal Research Institute
- Tel Aviv University
- Zhejiang University
- Shandong University
- Zhongshan Medical University
- University of Minnesota
- University of Lyon
- The University of Hong Kong
- Shantou University
- Shiraz University
- +2 more
Organization Involved with Phase 3 Indications (38)
- Roche
- Genentech
- Novartis
- Bellus Health Inc
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Emory University
- Guangxi Medical University
- Guangzhou Medical University
- Ohio State University
- Radboud University
- Sichuan University
- University of Heidelberg
- University of Michigan
- University of Alberta
- Wenzhou Medical University
- All India Institute of Medical Sciences
- Tsinghua University
- Food and Drug Administration
- Jiao Tong University
- University of Limoges
- Southern Medical University
- National University of Singapore
- National Taiwan University
- Sun Yat-Sen University
- Mario Negri Institute
- Asahi Kasei Pharma
- Free University of Brussels
- University of Genoa
- 1st People's Hospital of Foshan
- University of Paris
- +8 more
Organization Involved with Phase 2 Indications (7)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (9)